French biotech Abivax’s oral drug obefazimod demonstrated statistically significant clinical remission rates in twin Phase 3 trials for moderate to severe ulcerative colitis, surpassing previous Phase 2 data. The pooled 16.4% placebo-adjusted remission rate at week 8 positions obefazimod as a compelling candidate in the inflammatory bowel disease space. A maintenance study is ongoing with topline results expected in Q2 2026, followed by regulatory submissions. Despite a tight cash runway, market analysts have upgraded peak sales forecasts to $4 billion, highlighting the drug's efficacy, safety, and convenience.